Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) released its quarterly earnings data on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26), FiscalAI reports. The company had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.

Coya Therapeutics Stock Down 4.6%

NASDAQ COYA opened at $4.53 on Monday. The company has a market capitalization of $94.77 million, a price-to-earnings ratio of -4.08 and a beta of 0.23. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $7.75. The stock has a fifty day simple moving average of $4.77 and a 200 day simple moving average of $5.59.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently made changes to their positions in COYA. XTX Topco Ltd acquired a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $192,000. Occudo Quantitative Strategies LP acquired a new position in shares of Coya Therapeutics in the fourth quarter worth approximately $66,000. Millennium Management LLC bought a new stake in Coya Therapeutics in the fourth quarter valued at approximately $121,000. 683 Capital Management LLC bought a new stake in Coya Therapeutics in the fourth quarter valued at approximately $465,000. Finally, Cetera Investment Advisers acquired a new stake in Coya Therapeutics during the 4th quarter valued at approximately $128,000. Institutional investors own 39.75% of the company’s stock.

Analysts Set New Price Targets

COYA has been the topic of several recent research reports. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, February 18th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Finally, Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, January 8th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.